Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision loss.
Mason Reed 
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision loss.
This story was reported by AL.com. Read the full story at AL.com.
Image: Brittany Peterson / AL.com
